Skip to content
Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
About Us
APPROACH
CAREERS
LICENSING
CONTACT US
Focus Areas
OBESITY
IMMUNOLOGY
Pipeline
ALL ASSETS
INHBE siRNA
IL-13 x TSLP
Updates
ALL UPDATES
PRESS RELEASES
VIDEOS
Investors
INVESTOR OVERVIEW
PRESS RELEASES
EVENTS & PRESENTATIONS
STOCK INFORMATION
FINANCIALS & FILINGS
Contact us
Connect with Us
Leave us a message and some of your contact info and we’ll be in touch with you shortly.
Meet with us!
LinkedIn
This field is for validation purposes and should be left unchanged.
Name
(Required)
First
Last
Work email
(Required)
Phone
Company
(Required)
Which best describes you?
(Required)
Which best describes you?*
Interest in licensing Pre-Clinical Assets
Interest in licensing Phase 1 Assets
Interest in licensing Phase 2 Assets
Interest in licensing Phase 3/ Commercial Assets
We are a Clinic/ Site
Message
By submitting, you are agreeing to our
terms
and
privacy policy
Δ
Clear search querie